FFA
EW icon

Freedman Financial Associates’s Edwards Lifesciences EW Stock Holding History

Freedman Financial Associates’s Portfolio EW Stock Details EW Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q2 		– Sell
-135
Closed -$16K – 127
2022
Q1 		$16K Hold
135
– – 0.01% 318
2021
Q4 		$18K Hold
135
– – 0.01% 299
2021
Q3 		$15K Hold
135
– – 0.01% 315
2021
Q2 		$14K Hold
135
– – 0.01% 317
2021
Q1 		$11K Hold
135
– – 0.01% 346
2020
Q4 		$12K Buy
+135
New +$11.2K 0.01% 334

Other funds holding EW

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return
AllianceBernstein
AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Brown Advisory
Brown Advisory Baltimore, Maryland $60.9B AUM 15.24% 1-Year Est. Return
Sands Capital Management
Sands Capital Management Arlington, Virginia $25.5B AUM 26.46% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Freedman Financial Associates's EW Position: Q2 2022 in Review

Freedman Financial Associates sold out of Edwards Lifesciences (EW) in Q2 2022, closing a stake of 135 shares — an estimated $16K sold.

Freedman Financial Associates first reported a position in EW in Q4 2020 and held it in 6 quarters. The position peaked at $18K in Q4 2021. 1,272 funds tracked by Wall St. Rank hold EW as of Q2 2022.

  • Freedman Financial Associates reported no remaining Edwards Lifesciences position as of Q2 2022 after selling out during the quarter.
  • Freedman Financial Associates sold 135 Edwards Lifesciences shares in Q2 2022, an estimated $16K.
  • Freedman Financial Associates first reported a position in Edwards Lifesciences in Q4 2020 and held it in 6 quarters.
  • Freedman Financial Associates's Edwards Lifesciences position peaked at $18K in Q4 2021.
  • 1,272 funds tracked by Wall St. Rank held Edwards Lifesciences as of Q2 2022.

Based on Freedman Financial Associates's 13F filing for Q2 2022.